Elutia (NASDAQ:ELUT – Get Free Report) will release its earnings data after the market closes on Thursday, November 14th.
Elutia Stock Performance
Elutia stock opened at $3.80 on Tuesday. Elutia has a 1-year low of $1.39 and a 1-year high of $5.24. The firm has a market capitalization of $129.43 million, a PE ratio of -1.33 and a beta of 0.76. The firm’s 50 day simple moving average is $3.76 and its 200 day simple moving average is $3.67.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Elutia in a report on Friday, September 6th.
About Elutia
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
See Also
- Five stocks we like better than Elutia
- EV Stocks and How to Profit from Them
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- These 3 Active ETFs Beat the S&P 500 Over the Last Five Years
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
